Norpramin safety information labeling update

The FDA and sanofi-aventis have notified healthcare professionals of changes to the Prescribing Information for Norpramin (desipramine HCl tablets) to reflect new safety information. The Warnings and Overdosage sections of the Norpramin labeling have been updated to include safety information stating that extreme caution should be used when Norpramin is given to patients with a family history of sudden death, cardiac dysrhythmias, and cardiac conduction disturbances; and that seizures precede cardiac dysrhythmias and death in some patients.

Norpramin is indicated for the treatment of depression in adults.

For more information visit www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm192655.htm.